First-in-human studies showed promising results with a significant higher tumor uptake, confirming the results in cell lines that showed an increased uptake of 77.3 ± 6.2% at 48 h compared to PSMA radioligands without the EB-binding motif (p < 0.01) [46,47]. This evidence concerns the gene FOLH1 and neoplasm.